Precigen, Inc. ROE

ROE of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2021 was -105.62% (a -57.16% decrease from previous year)
  • Annual ROE for 2020 was -246.52% (a 66.19% increase from previous year)
  • Annual ROE for 2019 was -148.34% (a 30.55% increase from previous year)
  • Twelve month ROE ending June 30, 2022 was -85.35% (a 12.76% increase compared to previous quarter)
  • Twelve month trailing ROE decreased by -25.55% year-over-year
Trailing ROE for the last four month:
30 Jun '22 31 Mar '22 31 Dec '21 30 Sep '21
-85.35% -75.69% -105.62% -114.64%
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Precigen, Inc.

Most recent ROEof PGEN including historical data for past 10 years.

Interactive Chart of ROE of Precigen, Inc.

Precigen, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -105.62%
2020 -246.52%
2019 -148.34%
2018 -113.63%
2017 -21.22%
2016 -29.29%
2015 -15.17%
2014 -20.7%
2013 -191.91%
2012 38.27%
2011 36.53%

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology